Suppr超能文献

新型口服抗凝药(NOACs)的处方量已超过华法林:探究医生如何选择抗凝治疗药物。

Prescribing of NOACs has outnumbered warfarin: exploring how physicians choose anticoagulant treatments.

作者信息

Eek Anne Katrine, Øie Erik, Granas Anne Gerd

机构信息

Regional Medicines Information & Pharmacovigilance Centre (RELIS), Oslo University Hospital HF Rikshospitalet, PO Box 4950 Nydalen, 0424, Oslo, Norway.

Diakonhjemmet Hospital, Diakonveien 12, 0370, Oslo, Norway.

出版信息

Eur J Clin Pharmacol. 2018 Mar;74(3):323-330. doi: 10.1007/s00228-017-2374-4. Epub 2017 Nov 17.

Abstract

PURPOSE

The development of non-vitamin K-dependent oral anticoagulants (NOACs) is a new alternative to treatment with warfarin. The purpose of this study was to explore drug prescription decisions of NOACs or warfarin from hospital physicians in cardiovascular departments.

METHODS

A qualitative study with focus group interviews was conducted in three different hospitals. The interview guide explored the background of prescribing anticoagulants (warfarin, dabigatran, rivaroxaban, and apixaban) and experiences with effect and side-effects they had observed in patients.

RESULTS

The systematic text condensation eluded four main themes: when to prescribe NOACs, concern about side-effects, pharmaceutical properties and patient adherence, and prescribing policy and intra-professional communication. All available anticoagulants were prescribed. However, no specific NOAC was preferred. Factors perceived as contraindications for NOACs varied among the doctors. Most had observed side-effects of NOACs; however, these rarely influenced prescribing decisions due to small differences in safety profiles. Few drug-drug interactions and fixed daily doses made NOACs easy to prescribe; but some doctors had experienced lack of drug effect for some patients. Non-adherence with NOACs was harder to spot. Some different prescribing cultures had evolved between the different hospitals and between general practitioners.

CONCLUSION

The hospital physicians chose anticoagulants based on patient conditions as renal function, bleeding risks, and drug interactions being the most common taken into account. They could not say which NOAC was best, and wish that future studies could compare the different NOACs, and not just compare with warfarin.

摘要

目的

非维生素K依赖型口服抗凝药(NOACs)的研发是华法林治疗的一种新选择。本研究旨在探讨心血管科医院医生对NOACs或华法林的用药处方决策。

方法

在三家不同医院进行了聚焦小组访谈的定性研究。访谈指南探讨了开具抗凝药(华法林、达比加群、利伐沙班和阿哌沙班)的背景以及他们在患者中观察到的疗效和副作用的经验。

结果

系统的文本浓缩得出四个主要主题:何时开具NOACs、对副作用的担忧、药物特性和患者依从性,以及处方政策和专业内沟通。所有可用的抗凝药都有处方。然而,没有特别偏好的特定NOAC。医生们认为的NOACs禁忌因素各不相同。大多数人观察到了NOACs的副作用;然而,由于安全性方面的差异较小,这些副作用很少影响处方决策。很少有药物相互作用且每日固定剂量使NOACs易于处方;但一些医生曾遇到部分患者药物效果不佳的情况。NOACs的不依从性更难发现。不同医院之间以及全科医生之间形成了一些不同的处方文化。

结论

医院医生根据患者情况选择抗凝药,其中肾功能、出血风险和药物相互作用是最常考虑的因素。他们无法说出哪种NOAC最好,并希望未来的研究能够比较不同的NOACs,而不仅仅是与华法林进行比较。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验